Charting the Multi-level Molecular Response to Palbociclib in ER-Positive Breast Cancer
Kavalipati, A.; Aponte, A.; Sullivan, M. E.; Whittington, S. L.; Martinez, J. C.; Goda, G.; Aleman, M. M.; Emanuele, M. J.; Dominguez, D.
Show abstract
The addition of CDK4/6 inhibitors to endocrine therapy has significantly improved outcomes in HR+/HER2-breast cancer. However, variable patient responses and acquired resistance remain a clinical challenge. We therefore defined the comprehensive molecular response to palbociclib, the most clinically used CDK4/6 inhibitor. Global analyses of gene expression, protein abundance, splicing, and chromatin accessibility revealed broad patterns and specific changes that result from CDK4/6-inhibition in breast cancer cells. We uncovered unexpected feedback between CDK4/6 and estrogen-response signaling, which has clear clinical implications. We also revealed a widespread alternative splicing program that partially overlapped with genes whose expression is regulated, and which is expected to impact protein function. These molecular changes nominated combination therapies that interfere with the activation of CDKs or ER. Accordingly, co-targeting CDK7, which regulates CDK2, CDK4/6 and ER, additively impacted cell fitness. Collectively, these data reveal a complex, multi-tiered response to CDK4/6 inhibition, with implications for therapeutic efficacy.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- High resolution profiling of cell cycle-dependent protein and phosphorylation abundance changes in non-transformed cells 95%
- WEE1 inhibitors trigger GCN2-mediated activation of the integrated stress response 95%
- CDK4 inactivation balances resistance to apoptosis with heightened metabolic sensitivity in triple negative breast cancer cells 95%
Similar papers in this journal
- eIF4A controls translation of estrogen receptor alpha and is a therapeutic target in advanced breast cancer 96%
- CHAMP1 Complex Promotes Heterochromatin Assembly and Reduces Replication Stress 95%
- CRISPR metabolic screen identifies ATM and KEAP1 as targetable genetic vulnerabilities in solid tumors. 95%
Similar papers in this journal
- D-type cyclins regulate DNA mismatch repair in the G1 and S phases of the cell cycle, maintaining genome stability 95%
- A redox switch in p21-CDK feedback during G2 phase controls the proliferation-cell cycle exit decision 95%
- RAPIDASH: A tag-free enrichment of ribosome-associated proteins reveals compositional dynamics in embryonic tissues and stimulated macrophages 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.